Figure 2: Patient with a large goiter, prominent on the left side of the neck
Hence, in case of persistent albuminuria and/or uncontrolled metabolic risks (i.e., inadequate glycemic control, hypertension, overweight/obesity) on SGLT2i therapy, GLP-1RAs should be considered as the preferential add-on therapy in T2DM patients with chronic kidney disease
The mitochondrial-targeted SS-31 peptide and the exercise mimetic MOTS-c are additional longevity compounds where delivery route research continues to evolve
References Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P
doi:10.1093/gerona/glac135 GlyNAC Powerful Cellular Synergy Support glutathione production Fuel cellular energy Experience the proven synergy of Glycine and N-Acetyl-Cystene